XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 188,989 $ 170,405
Restricted cash 20,000 20,000
Accounts receivable 18,976 18,976
Prepaid & other current assets 3,230 62,356
Total current assets 231,195 271,737
In process R&D 1,101,760 1,101,760
Goodwill, net of impairment 5,988,230 5,988,230
Investment in GMP Bio at fair vlue 22,653,225 22,653,225
Total assets 29,974,410 30,014,952
Current liabilities:    
Accounts payable and accrued liabilities 2,440,807 2,437,321
Contingent consideration 2,625,000 2,625,000
Derivative liability on Notes 420,738 423,214
Total current liabilities 16,512,247 16,504,947
Total non-current liabilities 2,212,773 1,898,468
Total liabilities 18,725,020 18,403,415
Commitments and contingencies (Note 13)
Stockholders’ equity:    
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $.01 par value; 750,000,000 shares authorized; 399,684,128 and 399,184,128 issued and outstanding, respectively 3,996,839 3,991,839
Additional paid-in capital 41,763,054 41,655,026
Accumulated deficit (33,925,412) (33,516,736)
Total Oncotelic Therapeutics, Inc. stockholders’ equity 11,834,481 12,130,129
Non-controlling interests (585,091) (518,592)
Total stockholders’ equity 11,249,390 11,611,537
Total liabilities and stockholders’ equity 29,974,410 30,014,952
Related Party [Member]    
Current liabilities:    
Accounts payable to related party 344,526 344,099
Convertible debt and short-term debt, net of costs 2,866,659 2,608,356
Convertible long-term debt, net of costs 125,000 125,000
Nonrelated Party [Member]    
Current liabilities:    
Convertible debt and short-term debt, net of costs 7,814,517 8,066,957
Convertible long-term debt, net of costs $ 2,087,773 $ 1,773,468